Last updated: February 15, 2026
mmary
Switzerland's Federal Institute of Intellectual Property (IGE) evaluates biopharmaceutical patents based on strict criteria for patentability, enforceability, and claim scope. Patent applicants must demonstrate novelty, inventive step, industrial applicability, and comply with exclusions. Enforceability hinges on clear claims, detailed disclosures, and prior art considerations. The scope of claims is shaped by Swiss patent law and international standards, emphasizing precise, supported language to prevent invalidation or circumvention.
What are the criteria for patentability of biopharmaceutical inventions in Switzerland?
Switzerland grants patents for inventions that are new, involve an inventive step, and are industrially applicable. Specific to biopharmaceuticals:
-
Novelty: The invention must not be disclosed publicly before filing, including prior publications, prior uses, or other disclosures. Public disclosures within 12 months before filing can be neutralized under Swiss law if the applicant files an international or Swiss patent application within that period.
-
Inventive Step: The invention must not be obvious to a person skilled in the art. Swiss courts and the EPO consider the state of the art, common general knowledge, and obvious combinations.
-
Industrial Applicability: The invention must have a specific, substantial, and credible utility, often in medical, therapeutic, or production contexts for biopharmaceuticals.
-
Excluded Subject Matter: Under Swiss law and European directives, products derived from human embryonic stem cells or methods involving gene editing that contravene ethical norms are excluded. Patents cannot cover methods of surgical or therapeutic treatment of the human or animal body.
How does Swiss law address the patentability of biopharmaceuticals involving biological material?
Switzerland adheres to the European Patent Convention (EPC) standards, permitting patents on inventions involving biological material if the material is isolated from its natural environment or produced by means of a technical process. The key is that the biological material must be clearly described, and the invention must provide a technical contribution, such as a new gene sequence, antibody, or process for manufacturing.
What are the enforceability considerations for biopharmaceutical patents in Switzerland?
Enforceability depends on the strength of the patent’s claims and disclosures:
-
Clear Claims: Claims must precisely define the invention, avoiding ambiguity or overly broad language that could invite invalidation.
-
Adequate Disclosure: The application must enable a person skilled in the art to reproduce the invention, including detailed descriptions of biological materials, protocols, or composition.
-
Prior Art and Invalidity: The patent can be challenged based on prior publications, prior use, or obvious variations. Swiss courts have upheld invalidation based on insufficient disclosure or lack of inventive step.
-
Patent Litigation: Enforcement occurs via infringement proceedings in Swiss courts, which consider both the patent claims and the scope of the patent, including equivalents.
What governs the scope of claims in Swiss biopharmaceutical patents?
Swiss patent law emphasizes that claims should:
- Be supported by the description, clearly and precisely defining the invention.
- Cover only subject matter directly related to the disclosed invention.
- Avoid overly broad claims that encompass natural phenomena or known biological sequences unless they fulfill the inventive step criteria.
- Use consistent terminology throughout the application to improve enforcement and reduce ambiguity.
In biological patents, claims often include multiple product claims (such as specific antibodies), process claims (for manufacturing methods), and use claims (medical indications). Drafting should focus on avoiding either an exclusion for the declared use or an overly broad scope that can be narrowed during opposition or litigation.
What are recent policy trends impacting Swiss biopharmaceutical patents?
The Swiss Patent Office aligns with the European Patent Office (EPO) standards, but recent trends include:
- Stricter scrutiny of patent applications involving genetic engineering and gene editing.
- Increased emphasis on detailed disclosures to prevent broad claims covering naturally occurring phenomena.
- Greater opposition activity aimed at refining scope and validity at the pre- and post-grant stages.
References
[1] Swiss Federal Institute of Intellectual Property, "Guidelines for Patent Applications."
[2] European Patent Convention, Articles 52-57.
[3] Swiss Patent Law, Art. 53–55.
[4] EPO Guidelines for Examination, Part C, Chapter II.
[5] EPO Case Law on Biotech Patentability.
Key Takeaways
- Swiss biopharmaceutical patents require novelty, inventive step, and industrial applicability, with exclusions for certain biological methods.
- Clarity, detailed description, and support are essential for enforceability and defending against invalidation.
- Claim scope must be precise and supported, avoiding overly broad language that encompasses natural substances or phenomena.
- Recent policies emphasize detailed disclosures and scrutiny of genetic inventions, aligning with European standards.
- Litigation relies on clear claims and thorough disclosures, with enforcement typically through Swiss courts.
FAQs
1. Can Swiss patents cover naturally occurring biological materials?
No, patents generally cannot cover naturally occurring substances in their natural state. They can patent isolated, purified, or modified biological materials if they are the result of a technical process and fulfill patentability criteria.
2. How important is the description in Swiss biopharmaceutical patent applications?
Crucial. It must enable repetition by a skilled person and support the scope of the claims. Insufficient disclosures can lead to invalidation or refusal.
3. Are gene editing methods patentable in Switzerland?
Yes, provided they involve technical modifications and do not violate ethical exclusions. Claims must be specific, well-supported, and demonstrate inventive step.
4. How does Swiss law treat 'second medical use' claims?
Swiss law permits 'second medical use' claims, which specify new therapeutic indications for known compounds, provided they meet inventive step requirements and are clearly described.
5. What are common grounds for patent invalidation in Swiss courts for biopharmaceutical patents?
Lack of novelty, insufficient disclosure, obviousness, or exclusion of subject matter under law. Disputes often center around claim scope and prior art.
Citations
[1] Swiss Patent Law, Art. 53–55.
[2] European Patent Convention, Articles 52-57.
[3] Swiss Federal Institute of Intellectual Property, "Guidelines for Patent Applications."
[4] EPO Guidelines for Examination, Part C, Chapter II.
[5] EPO Case Law.
